We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 39

Medicinova and Zhejiang Medicine announce joint venture in China
  • Shook Hardy & Bacon LLP
  • China, USA
  • March 10 2011

California-based biopharmaceutical company MediciNova Inc. and Zhejiang Medicine Co., a Chinese pharmaceutical manufacturer, have announced a joint venture to develop and commercialize MediciNova’s MN-221 in China


NASDAQ Biotechnology Index surpasses all-time high in 1Q13
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe


Royalty financing gains favor for VC biotech funding
  • Shook Hardy & Bacon LLP
  • USA
  • August 29 2013

According to a former venture capitalist (VC), a recent deal involving a royalty in exchange for a cash infusion to develop and commercialize a


Biotech investments rise in Q4 2012, but remain off for the year
  • Shook Hardy & Bacon LLP
  • USA
  • January 24 2013

Pricewatershouse Coopers LLP has released its fourth quarter (Q4) and final 2012 venture capital investment reports and notes that "Biotechnology


U.S. biotech sector shows IPO gains in 2013
  • Shook Hardy & Bacon LLP
  • USA
  • June 6 2013

According to Reuters, 14 biotech companies have gone public so far in 2013, marking a possible turnaround for the sector with a rising stock market


Molecular diagnostics company nets $27.7 million from common stock offering
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Illinois-based Nanosphere, Inc. has reportedly closed a public offering of more than 17 million shares of common stock at $1.75 per share, including


Biotech IPO boom continues
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

According to Xconomy's National Biotech Editor Luke Timmerman, the 24 biotech initial public offerings (IPOs) in 2013 are double those normally seen


Biotech raises $30 million to develop rare muscle disease treatments
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

San Francisco-based Audentes Therapeutics Inc. has closed a $30-million Series A financing round led by OrbiMed Advisors and including 5AM Ventures


Viropharma to acquire Swedish pharma in deal worth up to $164.6 million
  • Shook Hardy & Bacon LLP
  • USA
  • November 3 2011

Pennsylvania-based ViroPharma Inc. has reportedly signed a deal to acquire Swedish company DuoCort Pharma AB to expand its orphan disease commercial product pipeline


Pharma and biotech stocks rise, M&A and IPO values strong, licensing deals
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Market analysts commenting on the dramatic rise in the Nasdaq Biotech Index (up 27) and the Dow Jones US Pharma Index (up 21) in the first half of